StreetAlpha.app
Home › Stocks › PTGX

Protagonist Therapeutics, Inc (PTGX)

Healthcare
$121.40
▼ −2.11%
LAST CLOSE · NOV 20

Protagonist Therapeutics develops peptide and small molecule medicines for inflammatory, blood and metabolic diseases. It last closed at $121.40 on Nov 20, down 2.11% on the day. The next earnings report for PTGX is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, PTGX reported EPS of $3.07 on revenue of $274.4M, with revenue up 5723.6% from a year ago. Over its last 8 reports the stock moved an average of 3.0% the session after earnings. Over the last 12 months PTGX insiders bought $0 of stock on the open market and sold $87.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is PTGX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PTGX.

Key Stats

Last 12 months
Results
Revenue
$551.7M
+163.7% vs a year ago
Net income
$342.3M
+645.5% vs a year ago
EPS (diluted)
$4.73
+616.7% vs a year ago
Free cash flow
$109.1M
19.8% margin
Valuation
Market cap
$7.9B
65.3M shares
P/E
25.7
Price over 12 month EPS
Price to sales
14.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$498.3M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
65.3M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $27.4M$27.4MFY2021FY2022: $26.6M$26.6MFY2022FY2023: $60.0M$60.0MFY2023FY2024: $434.4M$434.4MFY2024FY2025: $46.0M$46.0MFY2025

From PTGX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
$3.07
Quarter ended Sep 2026
Year ago EPS
-$0.62
Same quarter last year
Revenue
$274.4M
+5723.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $2.01Dec '24Mar 2025: -$0.19Mar '25Jun 2025: -$0.55Jun '25Sep 2025: -$0.62Sep '25Dec 2025: -$0.70Dec '25Mar 2026: $0.05Mar '26Jun 2026: $2.29Jun '26Sep 2026: $3.07Sep '26Latest $3.07
Revenue by quarter
Dec 2024: $170.6MDec '24Mar 2025: $28.3MMar '25Jun 2025: $5.5MJun '25Sep 2025: $4.7MSep '25Dec 2025: $7.4MDec '25Mar 2026: $56.4MMar '26Jun 2026: $213.5MJun '26Sep 2026: $274.4MSep '26Latest $274.4M
How PTGX moved after its last 8 reports
Average move the session after a report ±3.0%
Nov 5, 2026After the close−2.4%
Aug 5, 2026After the close+6.5%
May 5, 2026After the close+4.8%
Feb 25, 2026After the close+1.5%
Nov 6, 2025After the close−0.3%
Aug 6, 2025After the close−5.4%
May 6, 2025After the close+2.6%
Feb 21, 2025Time not announced+0.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PTGXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PTGX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PTGX

Technical Analysis

PTGX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 11% below its 20 day and 14% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 32), near oversold. The nearest support is the 200 day average at $120.33, and the nearest resistance the Pivot at $122.49.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 4.7%/day
Key levels
$160.8152 week high+32.5%
$140.50100 day average+15.7%
$138.82Swing high (Nov 12)+14.3%
$138.1450 day average+13.8%
$134.8720 day average+11.1%
$124.82Pivot R1+2.8%
$122.49Pivot+0.9%
$121.40Last close
$120.33200 day average−0.9%
$119.06Pivot S1−1.9%
$118.27Swing low (Jun 29)−2.6%
$77.0052 week low−36.6%
Indicators
RSI (14)31.51Weak, oversold below 30Neutral
MACD-4.26Below its signal lineBearish
Stochastic12.2Near the bottom of its rangeOversold
ADX (14)26.6Trending down
Williams %R-95.1Oversold below −80, overbought above −20Oversold
CCI (20)-147.6Oversold below −100, overbought above 100Oversold
Rate of change−8.1%Change over 10 sessionsBearish
ATR (14)$5.68Typical daily range, 4.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PTGX

What happened before

See how PTGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PTGX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PTGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PTGXHow many large options trades hit PTGX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PTGX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲230 buying vs 137 selling
  • ▲Held by funds +3.2 pts
  • ▲Funds holding +37
  • ▼Superinvestors: 1 added, 2 cut
  • ▲Put/call 0.53 to 0.50
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding384347+10.7%
In funds' top 10910−10.0%
Held by funds119.5%116.3%+3.2 pts
New / increased82 / 14861 / 137+16.2%
Reduced / sold out93 / 4488 / 37+9.6%
Put/call ratio0.500.53−5.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTGX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PTGX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$87.8M22 sales · 7 insiders
51% of the selling was under pre-arranged trading plans.
2026-01 sold $14.1M2026-02 sold $3.2M2026-03 sold $12.2M2026-04 sold $185K2026-05 sold $14.3M2026-06 sold $2.0M2026-08 sold $14.9M2026-09 sold $26.6M2026-11 sold $339KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Arturo Molina MdChief Medical OfficerSale2,718$124.65$339K
Sep 30Asif AliCFOSale plan58,629$141.78$8.3M
Sep 10Dinesh V Ph D PatelPresident and CEOSale plan125,000$145.92$18.2M
Aug 11Dinesh V Ph D PatelPresident and CEOSale plan100,000$148.91$14.9M
Jun 23William D. WaddillDirectorSale plan9,000$117.94$1.1M
Jun 10William D. WaddillDirectorSale plan9,000$107.68$969K
Every insider buy and sale for PTGX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PTGX insider trades →

From SEC Form 4 filings by PTGX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTGX is in one of them and how their past PTGX trades turned out.

PTGX in the AI portfolios
Loading…

PTGX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTGX in an article yet. Here's the latest on the wider market.

PTGX in the news

About Protagonist Therapeutics

Protagonist Therapeutics is a drug discovery and development company based in Newark, California. It is developing medicines for inflammatory skin conditions, a rare blood disorder called polycythemia vera, and obesity. Its key candidates include Icotyde, a treatment for plaque psoriasis being developed with Johnson & Johnson, and rusfertide, an injectable therapy for polycythemia vera developed with Takeda. These medicines are intended for patients with these conditions, and its partners are large drugmakers.

Headquarters
Newark, CA